Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis. - Wikidata - awgldk - TriplyDB

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

http://www.wikidata.org/entity/Q34251223

about

Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, ra

P2860

Q31074302-5250FBF5-7BB4-4D9C-A314-43C8BFC06836

P2860

Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.

http://www.wikidata.org/entity/Q34251223

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@ast

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@en

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@nl

type

label

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@ast

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@en

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@nl

prefLabel

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@ast

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@en

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@nl

P1433

Q34251223-8B134644-21C3-49A8-A88B-9BF2EABDE009

P1476

Q34251223-C6862737-0C56-427F-AB16-9F94D5210C84

P2093

Q34251223-15B5EE31-3B1A-4639-8764-3354D5C345E1

Q34251223-241E6573-57AF-4717-A526-C15960819E1B

Q34251223-704192C7-BA1C-491A-9E31-5A5A63EABEE7

Q34251223-85BE9635-C7FE-410E-BA3E-692BB047B65C

Q34251223-D6291C1F-711F-48C5-99BA-90A2D7BB811E

Q34251223-D79D10A3-88FF-45C6-BFE5-90160BA7F105

Q34251223-EBB0889D-8E82-4A5B-A1EF-E77AF1BE5FB9

P2860

Q34251223-09E1E75D-DFEA-4FB4-90DA-D20ACE7385E2

Q34251223-0BC732AB-C0AB-4CBD-949E-BA398ADA432F

Q34251223-1705D2FD-E322-4DB3-A33F-D5A98E49B2A7

Q34251223-1EFE8318-04A1-4E55-8E6B-580396670F8E

Q34251223-2412C804-1E04-4A7F-9632-C5791E71F220

Q34251223-30F0AED9-569B-4887-AB5C-4CE317A355DB

Q34251223-3682AD82-E407-4D60-998D-6B294EB4AA74

Q34251223-3A544BE4-B632-49D6-854B-B92C2EDB7E3C

Q34251223-3C8D9ED7-65E3-4FCA-91AD-315E789D9CCD

Q34251223-3F5D545C-3F25-4398-9CAC-B9F03FA79624

P304

Q34251223-FC22F10E-433F-4EF0-A262-43815F5AF99B

P31

Q34251223-A4617985-65E1-467E-9AFF-547F76D73A15

P356

Q34251223-C009A48F-4B59-495C-8130-E84918CA51A2

P478

Q34251223-537F1E3B-28D0-44E9-85DE-E025CC668089

P50

Q34251223-5C7559B9-BA48-4006-8D52-ADF8C058D89A

Q34251223-6BEB896A-530B-4055-B254-7592714BC750

P577

Q34251223-AA779CF0-FCE4-4615-92E1-791A0282F572

P698

Q34251223-B21EDD6C-7769-4BEA-B772-C8069AC43731

P932

Q34251223-816A9CE2-EAE5-4005-90BA-D3610C9922C4

P356

P1433

Journal of the International AIDS Society

P1476

Lopinavir/r no longer recommen ...... rative effectiveness analysis.

@en

P2093

Christian Pradier

http://www.w3.org/2001/XMLSchema#string

David Rey

http://www.w3.org/2001/XMLSchema#string

FHDH ANRS CO4 (French Hospital ...... herches sur le Sida, cohort 4)

http://www.w3.org/2001/XMLSchema#string

Françoise Brun-Vezinet

http://www.w3.org/2001/XMLSchema#string

Saadia Mokhtari

http://www.w3.org/2001/XMLSchema#string

Valérie Potard

http://www.w3.org/2001/XMLSchema#string

Willy Rozenbaum

http://www.w3.org/2001/XMLSchema#string

P2860

The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.

Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

Class-sparing regimens for initial treatment of HIV-1 infection.

Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.

Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort.

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

P304

19070

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7448/IAS.17.1.19070

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Costagliola

Isabelle Poizot-Martin

P577

2014-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25261780

http://www.w3.org/2001/XMLSchema#string

P932

4176690

http://www.w3.org/2001/XMLSchema#string